Guardant Health (GH) and Pfizer, (PFE) disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.
Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.
The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.
Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.
Price: 46.30, Change: +0.66, Percent Change: +1.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。